The role of postoperative radiotherapy for thymomas: a multicentric retrospective evaluation from three Italian centers and review of the literature.

3D-CRT Thymoma intensity-modulated radiotherapy (IMRT) postoperative radiotherapy (PORT) review

Journal

Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916

Informations de publication

Date de publication:
Dec 2020
Historique:
entrez: 15 1 2021
pubmed: 16 1 2021
medline: 16 1 2021
Statut: ppublish

Résumé

Thymoma is a rare mediastinal neoplasia. Surgery is the backbone of the treatment, but the role of postoperative radiotherapy (PORT) remains controversial. We aimed to obtain data on survival and safety in patients treated with PORT in three different Italian institutions. We retrospectively analyzed 183 consecutive patients who underwent surgery from 1981 to 2015. According to the Masaoka-Koga staging system, 39.3%, 32.7%, 18.6% and 9.8% patients were in stage I, II, III and IV of disease, respectively. PORT was indicated in 114 patients (62.3%), while 69 subjects underwent surgery alone. Complete resection was obtained in 68 patients who underwent PORT. Adverse events (AEs) were graded according to CTCAE v4.0. We analyzed the recent literature to describe the current reports on PORT for resected thymoma. Mean follow-up was 130 months (range, 3-417 months). Overall survival (OS) at 1-, 5- and 10-year from surgery was 98.3%, 90.2% and 69.7% respectively. One-, 5- and 10-year disease specific survival (DSS) was 98.9%, 92.3% and 89.8% respectively. Disease free survival (DFS) at 1, 5 and 10 years from surgery was 96.7%, 88.3% and 82.8% respectively. Univariate analysis showed that complete resection, cell histology A-AB-B1 and stages I-II were significant predictors of better DSS and DFS. Multivariate analysis showed that sex, R0 margins and WHO histology was independent prognostic factors. Among patients treated with PORT, a trend towards better OS was evident with Masaoka stage I-II (P=0.09). Patients with R0 margins treated with PORT showed better OS and DSS (P=0.05). No differences in DSS for performance status (P=0.70), WHO histology (P=0.19), paraneoplastic syndrome (P=0.23) and surgical procedure (P=0.53) were evident. Patients treated with PORT had a higher level of acute AEs compared to surgery alone, but none of these was graded ≥3. Our results confirmed that patients with incompletely resected thymoma had the worst OS and DSS. High grade acute toxicity was not different between PORT and surgery alone. Other trials reported a significant benefit in OS, DSS and DFS in stage IIb-IV thymoma treated with PORT.

Sections du résumé

BACKGROUND BACKGROUND
Thymoma is a rare mediastinal neoplasia. Surgery is the backbone of the treatment, but the role of postoperative radiotherapy (PORT) remains controversial. We aimed to obtain data on survival and safety in patients treated with PORT in three different Italian institutions.
METHODS METHODS
We retrospectively analyzed 183 consecutive patients who underwent surgery from 1981 to 2015. According to the Masaoka-Koga staging system, 39.3%, 32.7%, 18.6% and 9.8% patients were in stage I, II, III and IV of disease, respectively. PORT was indicated in 114 patients (62.3%), while 69 subjects underwent surgery alone. Complete resection was obtained in 68 patients who underwent PORT. Adverse events (AEs) were graded according to CTCAE v4.0. We analyzed the recent literature to describe the current reports on PORT for resected thymoma.
RESULTS RESULTS
Mean follow-up was 130 months (range, 3-417 months). Overall survival (OS) at 1-, 5- and 10-year from surgery was 98.3%, 90.2% and 69.7% respectively. One-, 5- and 10-year disease specific survival (DSS) was 98.9%, 92.3% and 89.8% respectively. Disease free survival (DFS) at 1, 5 and 10 years from surgery was 96.7%, 88.3% and 82.8% respectively. Univariate analysis showed that complete resection, cell histology A-AB-B1 and stages I-II were significant predictors of better DSS and DFS. Multivariate analysis showed that sex, R0 margins and WHO histology was independent prognostic factors. Among patients treated with PORT, a trend towards better OS was evident with Masaoka stage I-II (P=0.09). Patients with R0 margins treated with PORT showed better OS and DSS (P=0.05). No differences in DSS for performance status (P=0.70), WHO histology (P=0.19), paraneoplastic syndrome (P=0.23) and surgical procedure (P=0.53) were evident. Patients treated with PORT had a higher level of acute AEs compared to surgery alone, but none of these was graded ≥3.
CONCLUSIONS CONCLUSIONS
Our results confirmed that patients with incompletely resected thymoma had the worst OS and DSS. High grade acute toxicity was not different between PORT and surgery alone. Other trials reported a significant benefit in OS, DSS and DFS in stage IIb-IV thymoma treated with PORT.

Identifiants

pubmed: 33447442
doi: 10.21037/jtd-2019-thym-09
pii: jtd-12-12-7518
pmc: PMC7797870
doi:

Types de publication

Journal Article

Langues

eng

Pagination

7518-7530

Commentaires et corrections

Type : ErratumIn

Informations de copyright

2020 Journal of Thoracic Disease. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-2019-thym-09). The series “Thymoma” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Références

J Thorac Oncol. 2016 Oct;11(10):1785-92
pubmed: 27346413
J Thorac Cardiovasc Surg. 1997 Jan;113(1):55-63
pubmed: 9011702
Cancer. 2002 Jun 15;94(12):3115-9
pubmed: 12115342
Ann Thorac Surg. 2003 Sep;76(3):878-84; discussion 884-5
pubmed: 12963221
Onco Targets Ther. 2016 Jul 22;9:4517-26
pubmed: 27524907
Zhongguo Fei Ai Za Zhi. 2016 Jul 20;19(7):465-72
pubmed: 27339724
J Clin Oncol. 2004 Apr 15;22(8):1501-9
pubmed: 15084623
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S143-7
pubmed: 25396312
J Thorac Oncol. 2017 Nov;12(11):1715-1722
pubmed: 28774861
Chin Med J (Engl). 2013;126(11):2186-91
pubmed: 23769581
Cancer. 2015 Apr 1;121(7):1008-16
pubmed: 25565590
Am J Clin Oncol. 2016 Jun;39(3):223-7
pubmed: 24517958
J Thorac Oncol. 2009 Jan;4(1):119-26
pubmed: 19096319
Ann Thorac Surg. 2012 Jun;93(6):1822-8; discussion 1828-9
pubmed: 22551847
J Thorac Oncol. 2017 Apr;12(4):734-744
pubmed: 28126540
Clin Lung Cancer. 2019 Jan;20(1):e91-e96
pubmed: 30327246
Clin Immunol. 2016 Oct;171:12-17
pubmed: 27497628
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S304-12
pubmed: 20859124
J Thorac Oncol. 2014 Jul;9(7):1018-1022
pubmed: 24926546
Ann Thorac Surg. 2003 Nov;76(5):1635-41; discussion 1641-2
pubmed: 14602300
Ann Thorac Surg. 2016 Jan;101(1):305-10
pubmed: 26363651
Chin Med J (Engl). 1999 Feb;112(2):136-8
pubmed: 11593579
J Thorac Oncol. 2015 Sep;10(9):1357-1363
pubmed: 26280586
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S65-72
pubmed: 25396314
J Med Invest. 2008 Feb;55(1-2):17-28
pubmed: 18319541
J Thorac Oncol. 2008 Jan;3(1):75-81
pubmed: 18166844
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):51-56
pubmed: 27913462
Ann Thorac Surg. 2006 Jun;81(6):2328-34
pubmed: 16731193
J Thorac Oncol. 2014 May;9(5):596-611
pubmed: 24722150
J Thorac Oncol. 2016 Dec;11(12):2218-2226
pubmed: 27544056
J Thorac Cardiovasc Surg. 1996 Aug;112(2):376-84
pubmed: 8751506
Eur J Cancer. 2008 Jan;44(1):123-30
pubmed: 18068351
J Thorac Dis. 2016 May;8(5):901-10
pubmed: 27162665
J Thorac Oncol. 2010 Sep;5(9):1454-60
pubmed: 20651611
Int J Radiat Biol. 2018 May;94(5):495-502
pubmed: 29553917
Int J Surg. 2018 May;53:345-349
pubmed: 29673690
Eur J Cardiothorac Surg. 2016 Jun;49(6):1545-52
pubmed: 26670806
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1797-801
pubmed: 21596484
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1129-36
pubmed: 27026316
Eur J Cardiothorac Surg. 2014 Sep;46(3):361-8
pubmed: 24482389
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):440-5
pubmed: 19427738

Auteurs

Alessio Bruni (A)

Radiotherapy Unit, Hematology and Oncology Department, University Hospital of Modena, Modena, Italy.

Alessandro Stefani (A)

Division of Thoracic Surgery, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy.

Marco Perna (M)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.

Paolo Borghetti (P)

Department of Radiation Oncology, Spedali Civili of Brescia, Brescia, Italy.

Niccolò Giaj Levra (N)

Department of Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy.
Department of Oncology, University of Turin, Torino, Italy.

Elisa D'Angelo (E)

Radiotherapy Unit, Hematology and Oncology Department, University Hospital of Modena, Modena, Italy.

Alessandra D'Onofrio (A)

Department of Radiation Oncology, Spedali Civili of Brescia, Brescia, Italy.

Laura Rubino (L)

Radiotherapy Unit, Hematology and Oncology Department, University Hospital of Modena, Modena, Italy.

Luca Frassinelli (L)

Radiotherapy Unit, Hematology and Oncology Department, University Hospital of Modena, Modena, Italy.

Viola Salvestrini (V)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.

Matteo Mariotti (M)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.

Filippo Alongi (F)

Department of Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy.
Department of Oncology, University of Turin, Torino, Italy.

Alessandro Gonfiotti (A)

Thoracic Surgery Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.

Lorenzo Livi (L)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.

Vieri Scotti (V)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.

Classifications MeSH